A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Public ClinicalTrials.gov record NCT06308978. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT06308978
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Fate Therapeutics
- Industry
- Enrollment
- 244 participants
Conditions and interventions
Conditions
Interventions
- Bendamustine Drug
- Cyclophosphamide Drug
- FT819 Drug
- Fludarabine Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 27, 2024
- Primary completion
- Sep 29, 2027
- Completion
- Sep 29, 2042
- Last update posted
- Apr 30, 2026
2024 – 2042
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation | Fullerton | California | 92835 | Recruiting |
| University of California Irvine | Irvine | California | 92868 | Recruiting |
| Children's Hospital Los Angeles Division Of Rheumatology | Los Angeles | California | 90027 | Recruiting |
| University of California San Francisco | San Francisco | California | 94110 | Recruiting |
| University of Louisville | Louisville | Kentucky | 40202 | Recruiting |
| University of Minnesota Medical School | Minneapolis | Minnesota | 55455 | Recruiting |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | Recruiting |
| Montefiore Medical Center | New York | New York | 10467 | Recruiting |
| Duke University Health System | Durham | North Carolina | 27705 | Recruiting |
| MetroHealth | Cleveland | Ohio | 44109 | Recruiting |
| University of Oklahoma | Oklahoma City | Oklahoma | 73019 | Recruiting |
| Jefferson Einstein Hospital Philadelphia | Philadelphia | Pennsylvania | 19141 | Recruiting |
| Regional One Health | Memphis | Tennessee | 38103 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06308978, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06308978 live on ClinicalTrials.gov.